Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure--SIGNAL-HF (Swedish Intervention study--Guidelines and NT-proBNP AnaLysis in Heart Failure).
about
Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysisNatriuretic peptides as biomarkers in heart failureB-type natriuretic peptide-guided treatment for heart failure.The potential value of integrated natriuretic peptide and echo-guided heart failure management.Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs.Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trialsDoes B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials.Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study.NT-proBNP: A Guide to Improve the Management of Patients with Heart Failure.A review on B-type natriuretic peptide monitoring: assays and biosensorsModel-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure.Heart failure highlights in 2010.Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction.Updating the role of natriuretic peptide levels in cardiovascular disease.Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure.The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure.Natriuretic peptide-guided therapy: further research required for still-unresolved issues.Natriuretic peptide-guided heart failure management.A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods.B-type natriuretic peptide-guided therapy: a systematic review.Using biomarkers to guide heart failure management.Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives.Can Natriuretic Peptides be Used to Guide Therapy?Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.Responder to BNP-guided treatment in heart failure. The process of defining a responder.The benefits of using a heart failure management programme in Swedish primary healthcare.Use of novel and conventional biomarkers for management of patients with heart failure.Should we revise our approach to 'optimal medical therapy'? The case of chronic heart failure.Brain natriuretic peptide-guided management of chronic heart failure: first do no harm.Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure.Natriuretic peptide-guided versus clinically guided therapy for chronic heart failure: careful expert clinical management can remove need for biomarker-tailored dosing adjustment.The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics.Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study).B-type natriuretic peptide or amino-terminal pro-B-type natriuretic peptide-guided treatment of heart failure: what is the next STEP?Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.Natriuretic peptide-guided management by the general practitioner: how to interpret the SIGNAL.
P2860
Q27012693-DD0D7353-9C7F-4BA0-B1E6-2C10B7039604Q27012872-9407A34E-92D1-4206-AD52-7347B1B4DFA1Q30238936-7066198B-56DA-429A-A047-59CDB998D236Q30434020-3F096510-C2E7-422A-A0E1-C6191E318440Q33677364-561600E9-A895-4977-9104-750126B059C1Q34324771-87759825-09E1-46BE-A85A-0D0E99FE70C2Q34614873-8EC4262F-369B-4024-9CF0-009F8E40B197Q35179984-72681DDA-6B4A-428B-92A5-86887B299A47Q35792547-4EA95DC7-7BD7-4FF6-A1A2-3B0D71DFCA63Q35932097-2E652FA6-743C-4A5D-B01A-B7AC1448E283Q37155044-641F4F06-2D29-4B97-99DE-34B87805A108Q37171880-5C5FBF34-89FD-42C4-983F-8F0AB2DB4829Q37576886-BA45C896-F878-4CC8-9F6C-51A366A1F5FEQ37857587-9C02B031-4769-4AF8-AD81-C23FBA23E319Q37956217-810187DD-0107-4BB8-B391-F4E38F93031BQ37959158-390BA7B1-EBF0-460F-B2C4-88052C3ED9A5Q37980254-5FCE760D-42C7-4F16-8B2D-B58FEAAAC11CQ38063118-74749000-2C57-4E9B-AE83-64C08C43B0A8Q38099221-B24B22EC-D2B7-4263-81E0-DF80B4907ABDQ38161695-6E991D6A-35B7-4114-8E39-9C907D821994Q38222335-1328FB45-CC2A-4D23-92ED-4E55693F9406Q38235223-88BBB123-0BA6-4A5B-8C0D-4967C29A6642Q38613842-194864D1-9F06-4E7F-AA46-193768C21B9AQ38756838-96DF16C8-675B-4C39-A76C-97F4B6EFD373Q38967512-89106E32-E454-46AA-B5D3-21D35E2CB5A4Q40280356-DD3FB1A4-3F2F-4D0F-AD12-0A22C4BFB7DFQ41604218-CEB1D7DE-D9D4-4262-BFB5-A415536CB5CEQ42674615-F6509B2B-5F13-4400-B1A7-072121BAA2C7Q43480625-A9DDA693-02BE-4183-BEF9-869AD359776DQ43722663-4E3DD662-305F-40CA-BDF2-BDEC9F93DAB3Q44566168-188C17FF-A324-4F77-9EB7-3791D3880A8BQ44885046-41A0B30B-35D3-480D-9C08-DA5911EA1218Q47157822-DE195332-7130-4913-89B5-9930B9497282Q47580144-08FC88BB-91E8-49A4-AEA9-B6A62F26A80EQ48047576-14E7979D-E5FE-4841-8516-E76D50233BD3Q48120145-3CF786E5-60C2-43CC-B03D-E656CC975565Q48930054-ACC24E91-0B37-48D4-A657-E509B741D80FQ50999983-14B59F25-F44D-4770-B43B-B66FDB8B2D25Q51631485-C14B79F4-402E-4B7E-A63F-1EC8586FAF10
P2860
Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure--SIGNAL-HF (Swedish Intervention study--Guidelines and NT-proBNP AnaLysis in Heart Failure).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Improved pharmacological thera ...... NP AnaLysis in Heart Failure).
@en
Improved pharmacological thera ...... nt of Heart Failure--SIGNAL-HF
@nl
type
label
Improved pharmacological thera ...... NP AnaLysis in Heart Failure).
@en
Improved pharmacological thera ...... nt of Heart Failure--SIGNAL-HF
@nl
prefLabel
Improved pharmacological thera ...... NP AnaLysis in Heart Failure).
@en
Improved pharmacological thera ...... nt of Heart Failure--SIGNAL-HF
@nl
P2093
P2860
P356
P1476
Improved pharmacological thera ...... NP AnaLysis in Heart Failure).
@en
P2093
Björn Eriksson
Gunilla Johansson
Hans Erntell
Hans Persson
Ulf Dahlström
P2860
P304
P356
10.1093/EURJHF/HFQ169
P577
2010-09-28T00:00:00Z